Steve Thorne

Steve Thorne

Company: Kalivir Immunotherapuetics

Job title: Chief Scientific Officer


Expression of a TGF-β Inhibitor from an Oncolytic Vaccinia Virus 2:30 pm

• The VET platform developed by Kalivir allows systemic delivery of oncolytic virus therapies to tumors • Oncolytic viruses express transgenes to high levels locally within a tumor, so reducing the safety concerns of systemic delivery of recombinant proteins or antibodies • Oncolytic viruses expressing a TGF-β mini-monomer to block TGF-β receptor activation display enhanced…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.